George Tsoukalas

TL;DR: A role for colchicine in the treatment of patients with coronavirus disease 2019 is suggested, with results suggesting a smaller increase in dimerized plasma fragment D compared with patients in the control group.

TL;DR: The SAVE-MORE trial as discussed by the authors evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure.

TL;DR: In this paper , the authors proposed the Severe COvid Prediction Estimate (SCOPE) score, derived from circulating concentrations of C-reactive protein, D-dimers, interleukin-6, and ferritin among patients not receiving non-invasive or invasive mechanical ventilation during the SAVE-MORE study, offers predictive accuracy for progression to severe respiratory failure or death within 14 days comparable to that of a suPAR concentration of ≥6 ng/mL (area under receiver operator characteristic curve 0.81 for both).

TL;DR: The SAVE-MORE trial as discussed by the authors showed that early anakinra treatment guided by elevated soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 pneumonia into respiratory failure.